Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective-Reference-Cited by-同舟云学术

Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective

Published:2020-01-20 Issue:2 Volume:20 Page:151-161
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Allen Patrick B.¹,Bonovas Stefanos²³,Danese Silvio²³^ORCID,Peyrin-Biroulet Laurent⁴

Affiliation:

1. Department of Gastroenterology, Ulster Hospital, South Eastern Trust, Dundonald, Belfast, UK

2. Department of Biomedical Sciences, Humanitas University, Milan, Italy

3. IBD Center, Humanitas Clinical and Research Center, Milan, Italy

4. Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1702020

Reference64 articles.

1. Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel Disease

2. Moving towards disease modification in inflammatory bowel disease therapy

3. Preventing disability in inflammatory bowel disease

4. Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study

5. Ulcerative colitis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus;Journal of Crohn's and Colitis;2024-02-17

2. Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis;Gastroenterology;2024-01

3. Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease;United European Gastroenterology Journal;2023-09-05

4. Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease;World Journal of Gastroenterology;2023-05-14

5. Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars;Pharmaceutics;2022-08-24